| 2014-07 |
Anaplastic lymphoma kinase (ALK) inhibitors: A review of design and discovery |
MedChemComm. 2014 Jul;5(9):1266-1279. |
 |
| 2014-05 |
Facile identification of dual FLT3-Aurora A inhibitors: A computer-guided drug design approach |
ChemMedChem. 2014 May;9(5):953-961. |
|
| 2014-05 |
Cover Picture: Facile identification of dual FLT3–aurora a inhibitors: A computer-guided drug design approach (ChemMedChem 5/2014) |
ChemMedChem. 2014 May;9(5):861. |
|
| 2013-09-22 |
A novel Aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment [Erratum:International Journal of Biological Sciences. 2013 Apr 29;9(4):403-411] |
International Journal of Biological Sciences. 2013 Sep 22;9(9):947. |
|
| 2013-07-25 |
Pronounced induction of endoplasmic reticulum stress and tumor suppression by surfactant-free poly(lactic-co-glycolic acid) nanoparticles via modulation of the PI3K signaling pathway |
International Journal of Nanomedicine. 2013 Jul 25;2013(8):2689-2707. |
|
| 2013-06-28 |
Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine aurora kinase inhibitor |
Journal of Medicinal Chemistry. 2013 Jun 28;56(13):5247-5260. |
|
| 2013-06 |
An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells |
PLoS ONE. 2013 Jun;8(6):Article number e65686. |
|
| 2013-05 |
Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules |
Proceedings of the National Academy of Sciences of the United States of America. 2013 May;110(19):E1779-E1787. |
|
| 2013-05 |
Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: The role of the DFG motif in the design of epidermal growth factor receptor inhibitors |
Journal of Medicinal Chemistry. 2013 May;56(10):3889-3903. |
|
| 2013-04-29 |
A novel Aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment |
International Journal of Biological Sciences. 2013 Apr 29;9(4):403-411. |
|
| 2013-02-20 |
Parallel screening of Wild-Type and drug-resistant targets for anti-resistance neuraminidase inhibitors |
PLoS ONE. 2013 Feb 20;8(2):Article number e56704. |
|
| 2013-01 |
3D-QSAR-assisted drug design: Identification of a potent quinazoline-based aurora kinase inhibitor |
ChemMedChem. 2013 Jan;8(1):136-148. |
|
| 2013-01 |
Substituent effects on the photorearrangements of unsymmetrically substituted diazinobarrelenes |
RSC Advances. 2013 Jan;3(4):1165-1178. |
|
| 2012-12 |
An efficient, mild and scalable synthesis of bioactive compounds containing the angelicin scaffold |
Journal of the Chinese Chemical Society. 2012 Dec;59(12):1548-1554. |
|
| 2012-09 |
Anti-influenza drug discovery: Identification of an orally bioavailable quinoline derivative through activity- and property-guided lead optimization |
ChemMedChem. 2012 Sep;7(9):1546-1550. |
|
| 2012-08-24 |
Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts |
PLoS ONE. 2012 Aug 24;7(8):Article number e43314. |
|
| 2012-02 |
Identification of BPR3P0128 as an Inhibitor of cap-snatching activities of influenza virus |
Antimicrobial Agents and Chemotherapy. 2012 Feb;56(2):647-657. |
|
| 2012-01 |
A High-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors |
Anticancer Research. 2012 Jan;32(1):147-151. |
|
| 2011-09 |
Synthesis and biological evaluation of 1-(4′-Indolyl and 6′-Quinolinyl) indoles as a new class of potent anticancer agents |
European Journal of Medicinal Chemistry. 2011 Sep;46(9):3623-3629. |
|
| 2011-09 |
Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway |
Journal of Virology. 2011 Sep;85(17):9114-9126 |
|
| 2011-08 |
BPR1K653, a novel aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells |
PLoS ONE. 2011 Aug;6(8):Article number e23485. |
|
| 2011-06 |
Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10) |
Expert Opinion on Therapeutic Patents. 2011 Jun;21(6):857-884. |
|
| 2011-04-28 |
Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-Fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents |
Journal of Medicinal Chemistry. 2011 Apr 28;54(8):3076-3080. |
|
| 2011-03-07 |
2-Amino-3,4,5-Trimethoxybenzophenones as Potent Tubulin Polymerization Inhibitors |
ChemMedChem. 2011 Mar 7;6(3):450-456. |
|
| 2010-10-28 |
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and michael acceptor group for maximal potency |
Journal of Medicinal Chemistry. 2010 Oct 28;53(20):7316-7326. |
|
